Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | HPGDS | O60760 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | SLC26A4 | O43511 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24484906 | 1.00 | MAPT (0.45) | MAPTTSHRLMNAGAAHPGDS | |
| SCHEMBL24484782 | 0.91 | SLC26A4 (0.48) | MAPTTSHRLMNAGAAHPGDS | |
| SCHEMBL29629710 | 0.91 | SLC26A4 (0.48) | MAPTTSHRLMNAGAAHPGDS | |
| SCHEMBL29629670 | 0.81 | KMT2A (0.48) | MAPTTSHRLMNAGAAHPGDS | |
| SCHEMBL24484796 | 0.81 | KMT2A (0.48) | MAPTTSHRLMNAGAAHPGDS | |
| SCHEMBL24470809 | 0.81 | CASP3 (0.62) | MAPTTSHRLMNAKMT2ASLC26A4 | |
| SCHEMBL24485378 | 0.80 | SLC26A4 (0.46) | MAPTTSHRLMNAGAAKMT2A | |
| SCHEMBL29629665 | 0.79 | GAA (0.42) | MAPTTSHRLMNAGAAHPGDS | |
| SCHEMBL24484320 | 0.79 | GAA (0.42) | MAPTTSHRLMNAGAAHPGDS | |
| SCHEMBL24484790 | 0.76 | RAB9A (0.46) | MAPTTSHRLMNAGAAHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2026-03-12 | — | — | US | claimed |
| US-12404266-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-09-02 | — | — | US | claimed |
| EP-4251616-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven (BE) | 2023-10-04 | — | — | EP | claimed |
| WO-2022112352-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-06-02 | — | — | WO | claimed |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2026-03-12 | — | — | US | disclosed |
| US-12404266-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-09-02 | — | — | US | disclosed |
| US-12209081-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-01-28 | — | — | US | disclosed |
| US-20240336602-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2024-10-10 | — | — | US | disclosed |
| WO-2022112352-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209081-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | TRPM4, TRPM6, TRPM2 | MAPT 2911/4885TSHR 3289/4885LMNA 3056/4885 |
| US-12404266-B2 | Heterocycle derivatives for treating TRPM3 mediated disorders | TRPM4, TRPM6, TRPM2 | MAPT 2911/4885TSHR 3289/4885LMNA 3056/4885 |
| US-20260070896-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM6, TRPV3, TRPM2 | MAPT 3196/4885TSHR 642/4885LMNA 2851/4885 |
| US-20240336602-A1 | HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM4, TRPM6, TRPM2 | MAPT 2911/4885TSHR 3289/4885LMNA 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.